Lbp Am Sa Acquires 47,859 Shares of BioNTech SE Sponsored ADR $BNTX

Lbp Am Sa boosted its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 15.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 353,329 shares of the company’s stock after buying an additional 47,859 shares during the period. Lbp Am Sa’s holdings in BioNTech were worth $34,845,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Financial Consulate Inc. bought a new stake in shares of BioNTech in the third quarter valued at approximately $36,000. LRI Investments LLC raised its position in shares of BioNTech by 234.6% during the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock valued at $47,000 after buying an additional 312 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after acquiring an additional 305 shares during the period. Hantz Financial Services Inc. lifted its position in shares of BioNTech by 472.0% in the 2nd quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock worth $61,000 after acquiring an additional 472 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of BioNTech by 40.8% during the 3rd quarter. GAMMA Investing LLC now owns 784 shares of the company’s stock valued at $77,000 after acquiring an additional 227 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Trading Down 2.1%

Shares of NASDAQ BNTX opened at $115.98 on Monday. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. The company’s fifty day moving average is $99.39 and its 200-day moving average is $103.62. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $126.77. The stock has a market cap of $26.12 billion, a price-to-earnings ratio of -44.10 and a beta of 1.40.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The company had revenue of $1.78 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the previous year, the firm posted $0.81 EPS. The business’s quarterly revenue was up 22.0% compared to the same quarter last year. Equities research analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on BNTX shares. Berenberg Bank restated a “buy” rating on shares of BioNTech in a research note on Friday. UBS Group raised BioNTech to a “hold” rating in a report on Thursday, December 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Friday, January 9th. TD Cowen reaffirmed a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. Finally, JPMorgan Chase & Co. decreased their price target on BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a research report on Thursday, October 23rd. Eleven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $140.03.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.